Speakers & Bios

John H. Hammergren, McKesson Corporation

John H. Hammergren is Chairman, President and Chief Executive Officer of McKesson Corporation. He has been a director of McKesson since 1999 and was elected President and CEO in 2001 and Chairman in 2002. He joined McKesson in January 1996.

Under Hammergren's leadership, McKesson has emerged as the leading provider of supply, information and care management solutions designed to reduce the cost and improve the quality of healthcare. During his tenure, the company has more than doubled its revenues to $106B, expanded into new markets and advanced to number 15 on the Fortune 500. It has also experienced a cultural transformation driven by the establishment of a set of core values, a commitment to continuous process improvement, and a collaborative approach to serving its customers.

In 2007 Hammergren co-authored the book, “Skin in the Game,” where he describes the history of our health care system, provides an explanation of its current state, and outlines the great strides that he sees being made in the near future. In 2009 Hammergren became the chairman of the Healthcare Leadership Council, a coalition of chief executives of the nation’s leading health care companies and organizations. Hammergren is a member of the Hewlett Packard board of directors. He is also a director of Nadro, S.A. de C.V., a leading pharmaceutical distributor in Mexico.

Hammergren earned a BA in business administration from the University of Minnesota and an MBA from Xavier University in Cincinnati.

Back to Top

William Hawkins, Medtronic

Chairman and Chief Executive Officer Bill Hawkins assumed the role of Chief Executive Officer of Medtronic, Inc. in August 2007 and became Chairman of the Board in August 2008. Hawkins was named President and Chief Operating Officer in May 2004 after joining Medtronic as Senior Vice President and President of Medtronic's Vascular business in January 2002.

Hawkins joined Medtronic from Novoste Corp., where he had been President and Chief Executive Officer since 1998. Earlier positions included Corporate Vice President and President of the Sherwood Davis and Geck organization of American Home Products; President of the Ethicon Endo-Surgery organization of Johnson & Johnson; President, Devices for Vascular Intervention and President U.S. Operations, for Guidant Corp.; and several increasingly responsible executive positions culminating in the presidency of the IVAC organization for Eli Lilly & Co. He began his medical technology career with Carolina Medical Electronics in 1977.

Hawkins received his Bachelor of Science degree in electrical and biomedical engineering from Duke University in 1976 where he also conducted medical research in pathology. He received a Master of Business Administration Degree from the Darden School of Business, University of Virginia, in 1982.

Hawkins is a member of the Board of Visitors of the Engineering School of Duke University and the Guthrie Theatre Board.

Back to Top

John C. Lechleiter, Eli Lilly and Company

John C. Lechleiter, Ph.D., is chairman, president, and chief executive officer of Eli Lilly and Company. Lechleiter served previously as president and chief operating officer of Lilly, beginning in 2005, when he also joined the board. In 2004, he became Lilly’s executive vice president for pharmaceutical operations. Prior to that, he had served as executive vice president for pharmaceutical products and corporate development since 2001.

Lechleiter received a bachelor of science degree in chemistry from Xavier University (Cincinnati, Ohio) in 1975. He subsequently studied organic chemistry as a National Science Foundation Fellow at Harvard University, where he received his master’s and doctorate degrees. In 2006, Lechleiter received an honorary doctorate of business administration from Marian University (Indianapolis).

Joining Lilly in 1979 as a senior organic chemist in process research and development, Lechleiter became head of that department in 1982. In 1984, he began serving as director of pharmaceutical product development for the Lilly Research Centre Limited in Windlesham, England.

He returned to the United States in 1986 as manager of research and development projects for Europe. In 1988, he became director of development projects management, and in 1989, he assumed additional responsibility for pharmaceutical regulatory affairs. In 1991, he was named executive director of pharmaceutical product development, and in 1993, he became vice president. He was appointed vice president of regulatory affairs in 1994. In 1996, he was named vice president for development and regulatory affairs. Lechleiter became senior vice president of pharmaceutical products in 1998.

He is a member of the American Chemical Society; Business Roundtable; and Business Council. Currently, Lechleiter serves on the boards of the Pharmaceutical Research and Manufacturers of America (PhRMA); Nike, Inc.; Xavier University; Fairbanks Institute (Indianapolis); Indianapolis Downtown, Inc.; the Central Indiana Corporate Partnership; and the United Way of Central Indiana.

Back to Top

Stephen P. MacMillan, Stryker Corporation

Stephen P. MacMillan is Chairman, President and Chief Executive Officer of Stryker Corporation and serves on its Board of Directors. Mr. MacMillan joined Stryker in 2003 as President and Chief Operating Officer, and was appointed CEO effective January 2005.

Mr. MacMillan began his career with Procter & Gamble in 1985 and later spent 11 years with Johnson & Johnson in both the U.S. and Europe, and was later named President of the joint venture between Johnson & Johnson and Merck.

In 2000, he joined Pharmacia Corporation where he oversaw five global businesses with revenues exceeding $2 billion and was a member of Pharmacia’s Executive Committee. Throughout his career, Mr. MacMillan has focused on consistently driving strong double-digit revenue and profit growth, and developing strong teams.

In 2008, Mr. MacMillan was elected to the Board of Directors of Texas Instruments. He also serves as a board member for the Greater Kalamazoo United Way and AdvaMed. He received a Bachelor of Arts degree in Economics from Davidson College and is a graduate of Harvard Business School’s Advanced Management Program. He is married and has two children.

Back to Top

Richard J. Meelia, Covidien Ltd.

Richard J. Meelia is Chairman, President, Chief Executive Officer and a Director of Covidien Ltd., a leading $10 billion global healthcare products company. The business, formerly known as Tyco Healthcare, spun off from parent company Tyco International on June 29, 2007.

Covidien manufactures, distributes and services a diverse range of medical devices, supplies, imaging products and pharmaceuticals, sold under industry-leading brand names such as Autosuture, Kendall, Mallinckrodt, Nellcor, Puritan Bennett, Syneture, United States Surgical, Valleylab and others. Covidien has more than 43,000 employees in 57 countries, and its products are sold in over 130 countries.

Mr. Meelia, 60, joined Kendall Healthcare Products Company, the foundation of the Tyco Healthcare business, as Group President in 1991 and became President of Tyco Healthcare in 1995. During the ensuing decade, he directed Tyco Healthcare’s acquisition, integration and product development efforts, growing the business from $600 million to the diverse $10 billion healthcare products leader it is today.

Prior to joining Kendall/Tyco Healthcare, Mr. Meelia was President of Infusaid, Inc., a division of Pfizer Hospital Products Group that manufactures and markets implantable infusion pumps and ports. Before that, he held sales and marketing positions with the Pharmaseal and McGaw divisions of the American Hospital Supply Corporation.

A graduate of Saint Anselm College, Mr. Meelia earned an MBA degree from Boston College.

Mr. Meelia is a member of the Board of Directors of Triangle, a career empowerment network for people with disabilities, and the Board of Directors of Massachusetts Hospital School. He serves on the Board of Governors of the Tufts Medical Center and the Board of Trustees of St. Anselm College.

Back to Top

Timothy Ring, CR Bard

Mr. Ring was named Chairman and Chief Executive Officer for C. R. Bard, Inc. as of August 8, 2003. He joined Bard in June 1992 as Corporate Vice President ? Human Resources and was promoted to Group Vice President ? International in December 1993. In November 1995, he was given additional responsibility for Interventional Cardiology and Electrophysiology. In January 1997, he also assumed additional responsibility for the Cardiac Assist and Cardiopulmonary Divisions and in April 1997, he was promoted to Group President for Coronary Vascular Products. In 1999, he was named Group President for Bard Electrophysiology and Peripheral Vascular Products and in 2002 was given additional responsibility for Bard Access Systems, Bard Europe and Corporate Healthcare Services.

Prior to Bard, he worked for Abbott Laboratories for nearly 10 years, most recently as Director of Personnel for the Hospital Products Division. Before that, he was General Manager for Abbott’s Australian, New Zealand and Indonesian operations, residing in Sydney. Prior to that, he was Director of Personnel for Pacific/Asia/Africa and Europe. From 1984 to 1986, he was also Director of Personnel for Latin America & South East Asia. He started at Abbott in 1983 as Assistant Personnel Manager for the Pharmaceutical Division. Before joining Abbott, Mr. Ring was employed by The General Motors Corporation. Mr. Ring has a B.S. in Industrial and Labor Relations from Cornell University.

He is a trustee for the Foundation of The University of Medicine & Dentistry of New Jersey and the HealthCare Institute of New Jersey, and serves on the Cornell University Life Sciences Advisory Board. Mr. Ring is also a member of the Board of Directors for C. R. Bard, Inc., AdvaMed, the medical device industry association, and NAM (National Association of Manufacturers).

Back to Top

Chris Viehbacher, Sanofi-aventis

Chris Viehbacher, born March 26, 1960, holds German and Canadian nationalities. He is a graduate of the Queens University (Ontario, Canada) and a certified public accountant.

After beginning his career at PriceWaterhouseCoopers, between 1988-2008 he acquired broad international experience in Europe, in the United States and in Canada with the GlazoSmithKline (GSK) company. In his last position, Chris Viehbacher was President, Pharmaceutical Operations North America, a member of the board and Co-Chairman of the Portfolio Management Board.

As of December, 1, 2008, Chris Viehbacher is a Sanofi-aventis board member, CEO and a member of the Strategy Committee. Chris Viehbacher is a Board member of PhRMA in the United States.

Chris Viehbacher is married with three children. He speaks French, English and German. He has lived in France for nine years and was made a knight of the French Legion of Honor in 2003.

Back to Top

William Weldon, Johnson & Johnson

William C. Weldon is Chairman of the Board and Chief Executive Officer of Johnson & Johnson. He assumed his current responsibilities in April, 2002. Previously Mr. Weldon served as Worldwide Chairman, Pharmaceuticals Group, and a Vice Chairman of the Board of Directors. He was elected to the Board in February, 2001.

Mr. Weldon joined Johnson & Johnson in 1971 in the sales and marketing department of its McNeil Pharmaceutical subsidiary. In 1982 he was named manager, ICOM Regional Development Center in Southeast Asia. Mr. Weldon was appointed executive vice president and managing director of Korea McNeil, Ltd., in 1984 and managing director of Ortho-Cilag Pharmaceutical, Ltd., in the U.K. in 1986. In 1989, he was named vice president of sales and marketing at Janssen Pharmaceutical in the U.S., and in 1992 he was appointed president of Ethicon Endo-Surgery.

In 1995 Mr. Weldon was named a company group chairman of Johnson & Johnson and Worldwide Franchise Chairman of Ethicon Endo-Surgery, the Johnson & Johnson affiliate that develops new procedures for minimally-invasive surgery and designs related products. In 1998 Mr. Weldon was promoted to the Executive Committee and named Worldwide Chairman, Pharmaceuticals Group.

Among his outside activities, Mr. Weldon is a member of the Board of Directors of JPMorgan Chase & Co and the US ? China Business Council. He is also Chairman of the CEO Roundtable on Cancer, A member of The Business Council, a member of The Business Roundtable and a member of the Healthcare Leadership Council. Mr. Weldon also serves as a member of the Board of Trustees for Quinnipiac University. He previously served as Chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA).

Mr. Weldon was born in Brooklyn, NY, and is a graduate of Quinnipiac University in Hamden, Connecticut. He and his wife have two children and one grandson.

Back to Top